Patient, Consumer Groups Decry Lack Of User Fee Funding For Post-Market Surveillance

Non-industry stakeholders criticized the medical device user fee agreement for not giving FDA enough funding, particularly to enhance post-market surveillance programs, during an FDA public meeting on user fee reauthorization.